Drugs in Dev. Endocrinology
Phase I
China 
Lead Product(s) : Bofanglutide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gan & Lee Reports Weight Loss Results in Phase 1 Study for Oral GLP-1 Agonist GZR18
Details : GZR18 tablet is an investigational, once-daily oral GLP-1 receptor agonist, which is being developing for the treatment of Type 2 Diabetes.
Product Name : GZR18
Product Type : Peptide
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : Bofanglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GB08
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kexing Gets Approval for Trial of Long-Acting Growth Hormone Drug
Details : GB08 is a long-acting growth hormone in the form of an Fc-fusion protein, which is being evaluated for the treatment of patients with pediatric growth hormone deficiency syndrome.
Product Name : GB08
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : GB08
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sciwind Biosciences Announces Positive Phase 1 Trial Results of XW004
Details : XW004 (ecnoglutide) is a long-acting, cAMP signaling biased, glucagon-like peptide-1 (GLP-1) analog. It is under phase 1 clinical development for the treatment of type 2 diabetes and obesity.
Product Name : XW003
Product Type : Peptide
Upfront Cash : Inapplicable
January 23, 2024
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ECC5004
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Neutron Therapeutics
Deal Size : $25.1 million
Deal Type : Series B Financing
Details : The proceeds will support the development of Eccogene’s clinical-stage programs including Phase I trial of ECC5004, a small molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and the Phase I trial of ECC4703, a THRb full agonist for NASH ...
Product Name : ECC5004
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 06, 2023
Lead Product(s) : ECC5004
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Neutron Therapeutics
Deal Size : $25.1 million
Deal Type : Series B Financing
Lead Product(s) : Bofanglutide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gan & Lee Pharmaceuticals Begins First-In-Human Trial in the U.S. for Investigational Drug, GZR18
Details : GZR18 is a glucagon-like peptide-1 receptor agonist (GLP-1RA) with potential to treat patients with type 2 diabetes.The primary objective of this Phase 1 study is to investigate safety and tolerability of GZR18 in healthy volunteers.
Product Name : GZR18
Product Type : Peptide
Upfront Cash : Inapplicable
October 03, 2022
Lead Product(s) : Bofanglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Adocia
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary objective of Phase 3 program is to demonstrate non-inferiority of BC Lispro on HbA1c reduction from baseline vs. Humalog. BioChaperone® Lispro (BC Lispro) is ultra-rapid prandial insulin containing insulin lispro and Adocia’s proprietary t...
Product Name : BioChaperone Lispro
Product Type : Peptide
Upfront Cash : Inapplicable
October 14, 2021
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Adocia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : LYFE Capital
Deal Size : $37.0 million
Deal Type : Series B Financing
Sciwind Biosciences Secures US$37 Million Series B Financing
Details : Sciwind Biosciences has completed a phase 1 clinical study of XW003, in an overseas clinical site, and phase 2 clinical trials including type II diabetes, obesity and non-alcoholic steatohepatitis (NASH), are expected to be initiated in China in 2021.
Product Name : XW003
Product Type : Peptide
Upfront Cash : Undisclosed
February 19, 2021
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : LYFE Capital
Deal Size : $37.0 million
Deal Type : Series B Financing
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The new data pertained to three proposed biosimilar Gan & Lee insulin analogs, insulin aspart (GL-ASP), insulin lispro (GL-LIS), and insulin glargine (GL-GLA), and were presented by the primary investigators from Profil, (Germany).
Product Name : GL-ASP
Product Type : Hormone
Upfront Cash : Inapplicable
February 07, 2021
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dorzagliatin,Empagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The PK results showed no impact of dorzagliatin and empagliflozin on respective PK properties under co-administration, supporting the us of this combination in the clinical setting.
Product Name : HMS5552
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2020
Lead Product(s) : Dorzagliatin,Empagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
